Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis and Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and Large Patient Populations
About CNS Pharmaceuticals, Inc.
- NASDAQ: $CNSP
- Notified: $2.00
- 07:02 EDT